Brief: Pharming Announces Positive Topline Results For Pediatric Clinical Trial Of Leniolisib

Pharming

11/12/2024 06:17

Dec 11 (Reuters) - Pharming Group NV  PHAR.AS :
    * ANNOUNCES POSITIVE TOPLINE DATA IN PEDIATRIC CLINICAL
TRIAL OF
LENIOLISIB
    * SEPARATE PHASE III TRIAL FOR CHILDREN AGED 1 TO 6 YEARS
ONGOING
    * NO DRUG RELATED SERIOUS ADVERSE EVENTS REPORTED
    * GLOBAL REGULATORY FILINGS FOR LENIOLISIB APPROVAL TO BEGIN
IN
2025
    * STUDY ENROLLED 21 CHILDREN WITH APDS AGES 4 TO 11 YEARS
    * LYMPHOPROLIFERATION IMPROVED WITH MEAN REDUCTION IN INDEX
LESION
SIZE
    * ELIGIBLE PATIENTS CONTINUE LENIOLISIB TREATMENT IN
OPEN-LABEL
EXTENSION TRIAL

Source text:  ID:nGNX3WlWKG 
Further company coverage:  PHAR.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))